Overview
Biotechnology and pharmaceutical manufacturers must recognize, understand, and address many legal and regulatory requirements associated with the research, development, pricing, promotion, marketing, and selling of their respective services and products—domestically and internationally.
Significant scrutiny on these industries from the public; federal, state, and international regulators; elected officials; and enforcement agencies continues. Therefore, entities operating in these industries must remain even more vigilant and knowledgeable about the legal and regulatory parameters affecting their companies in order to stay compliant and proactive in order to minimize risk.
Epstein Becker Green counsels companies and institutions operating in the different segments of biotechnology and pharmaceutical industries domestically and internationally. We provide comprehensive legal services relating to all aspects of the development of products, the U.S. Food and Drug Administration (FDA) regulatory approval process, government and third-party reimbursement concerns, and post-approval marketing, commercialization, and compliance requirements. Firm attorneys publish and present extensively at leading industry events and work actively on behalf of firm clients to both educate and advocate to federal and state government agencies and regulators on significant industry issues.
Services/Scope of Practice
Development of Life Science Products and FDA Regulatory Approval
- Providing FDA counseling relating to clinical trial registries and databases, grant-making procedures, and relationships with physicians investigators, and research institutions
- Developing and negotiating co-development, co-promotion, outsourcing, and other strategic research, development, and collaboration agreements
- Providing FDA counseling relating to labeling and advertising claims
Government and Third-Party Reimbursement
- Counseling on government pricing programs, including Medicaid Best Price, Average Sales Price, Competitive Acquisition Program, the Federal Supply Schedule, and the Public Health Service Act, and on VA pricing issues
- Providing counseling and strategic planning assistance regarding federal and state drug and device reimbursement programs
- Advising on the processes and strategies for obtaining coverage, coding, and payment for drugs and devices by government and private payors
- Providing regulatory counseling regarding product discount/rebate arrangements with distributors, GPOs, managed care organizations, long-term care facilities, physicians, institutions, specialty pharmaceutical suppliers, federal and state purchasers (including SPAPs and other state and federal pharmaceutical programs), and other purchasers
- Providing antitrust counsel related to manufacturer pricing issues
- Counseling on license agreements and co-promotional activities
Post-Approval Marketing, Commercialization, and Compliance
- Providing all facets of fraud and abuse counseling to manufacturers and their direct and indirect customers and/or purchasers relating to sales programs, marketing initiatives, and other collaborative programs and relationships, including disease management, medication therapy management, coupons, samples and sample cards, reimbursement support, grants, and patient assistant programs
- Providing advice relating to all aspects of health reform regulations, including the Sunshine Act and state reporting laws
- Supporting and counseling on manufacturer new product launches
- Providing health regulatory counsel relating to distribution and fee-for-service arrangements with MCPs and consumers
- Providing FDA counseling relating to promotional matters, non-promotional activities, continuing medical education activities, and good clinical and laboratory practices
- Providing all facets of counsel regarding post-market clinical trial research programs and grant administration
- Counseling on licensure and other accreditation standards
- Providing HIPAA privacy and security counseling relating to manufacturing, research, and marketing issues
Investigations, Litigation, and Administrative Matters
- Defending manufacturers in connection with false claim qui tam actions and other federal, state, and congressional health care fraud investigations and inquiries
- Negotiating corporate integrity agreements (CIAs) with the OIG
- Assisting with the implementation and monitoring of CIA compliance
- Providing counsel regarding the submission of voluntary disclosures to the OIG and/or other relevant regulators
- Defending manufacturers and their research partners in private actions related to clinical trial noncompliance and misconduct
- Preparing and assisting manufacturers for appearances at FDA administrative hearings
- Assisting manufacturers in responding to warning letters, notice-of-violation letters, and congressional inquiries
Corporate Compliance
- Developing and implementing all aspects of corporate compliance programs for manufacturers and their direct and indirect customers
- Conducting corporate effectiveness reviews/assessments of corporate compliance programs
- Developing training programs on corporate compliance for marketing and sales forces
- Assisting with the development of reporting systems and compliance monitoring and auditing priorities
- Assisting manufacturers with gap assessments and Board assessments
- Providing counsel in connection with internal compliance investigations
- Developing clinical trial research corporate compliance programs for manufacturers, clinical research organizations, and site management organizations, including compliance with Good Clinical Practices, human subject protection compliance procedures, and procedures regarding investigator-initiated research
- Developing research compliance programs addressing relationships with research sites, researchers, vendors, professional organizations, independent foundations, and other participants in the clinical research process
Policy and Legislation
- Monitoring and analyzing pending federal and state legislation, rulemaking, regulations, and guidance
- Providing assistance with the submission of comments in connection with pending legislation and proposed rules, regulations, and guidance
- Assisting with the preparation of testimony in connection with pending legislation
- Providing counsel regarding federal and state marketing, disclosure, sales, gift, compliance program, pricing, clinical trials, pedigree, and related reporting requirements
- Providing legislative industry updates and analyses
Federal and State Transparency Reporting
- Counseling clients on federal and state reporting requirements
- Conducting gap assessments
- Correcting compliance implementation deficiencies
- Addressing infrastructure and resource matters
- Implementing aggregate spend reporting systems
- Drafting policies, procedures, and working instructions
- Training employees, vendors, and health care professionals
- Responding to government agencies and proposed regulations
- Analyzing preemption matters
- Informing clients of federal and state law developments
Read less
Focus Areas
Services
Industries
Trending Issues
Experience
Contacts
- Member of the Firm
- Board of Directors / Member of the Firm
- Member of the Firm
Media
Events
Upcoming Events
Past Events
Insights
Insights
- Publications
In Genesis Case, South Carolina District Court Scraps HRSA Interpretation of “Patient” Under 340B Statute
9 minute read - Media CoverageConnie Wilkinson Quoted in “Stelara Biosimilar Tests Market Impact of Drug Price Program”3 minute read
- BlogsSharing Scientific Information with HCPs on Unapproved Uses of Medical Products: Dos and Don’ts Under FDA’s New Draft ...14 minute read
- PublicationsQuadrivalent Vs Trivalent Influenza Vaccines: Not A Simple Switch2 minute read
- PublicationsCMS Seeks Stakeholder Feedback About Medicare Transaction Facilitator Services for the Medicare Drug Price Negotiation ...4 minute read
- Media CoverageRichard Hughes Quoted in “An R.S.V. Shot for Infants Is in Short Supply. Here’s What to Know”4 minute read
- PublicationsPreventive Antibody Products Are Immunizations2 minute read
- PublicationsCalifornia Enacts Statute That Furthers Efforts to Move Toward a Unified Health Care Financing System11 minute read
- Media CoverageRichard Hughes Quoted in “RSV Vaccines Aren’t Covered by Medicare for These Vulnerable Groups”2 minute read
- BlogsCongress May Have a Vision for Psychedelic Regulation in the US5 minute read
- PublicationsORI Releases Notice of Proposed Rulemaking to Update 2005 Public Health Service Policies on Research Misconduct ...7 minute read
- BlogsFull Steam Ahead: FDA Releases Proposed LDT Rule in Advance of Looming Government Shutdown4 minute read
- PublicationsState Regulation of Pharmacy Benefit Managers: Tenth Circuit Holds That ERISA and Medicare Part D Preempt Key Parts of ...25 minute read
- PublicationsFTC Warns Against Contract Provisions It Believes Could Impede Its Investigations2 minute read
- PublicationsFTC’s Fight with House Judiciary Committee Goes Public2 minute read
- PublicationsAdditional Withdrawals of Long-Standing Guidance and Newly Proposed Merger Guidelines2 minute read
- PublicationsEuropean Commission Adopts an Adequacy Decision for a New EU-U.S. Data Privacy Framework6 minute read
- PublicationsPotential Hart-Scott-Rodino Changes on the Horizon3 minute read
- PublicationsWhat’s on the Agenda? Laboratory Developed Tests Added to the Unified Regulatory Agenda Signals FDA Movement Toward New ...26 minute read
- Firm Announcements
Elizabeth Scarola Named to the 2023 Florida Rising Stars List
6 minute read - Media CoverageHemant Gupta, Jeff McGoff, and Adelee Traylor Featured in “Epstein Becker Grows Health Care Practice in Dallas ...3 minute read
- Media CoverageHemant Gupta, W. Jeff McGoff, and Adelee Traylor Featured in “Wake Up Call: Laterals, Moves, In-House”1 minute read
- Firm AnnouncementsEpstein Becker Green Adds Health Care Transactional, Technology & IP Attorneys in Memphis and Dallas Amid Ongoing Expansion ...4 minute read
- PublicationsCMS Releases Its List of 43 Part B Rebatable Drugs for Q3: Inflation Reduction Act Updates7 minute read
- PublicationsA 20-Year Consent Order Prohibiting the Use of Non-Compete Agreements2 minute read
- PublicationsManufacturers Must Request Small Biotech Exception by July 3: Inflation Reduction Act Updates4 minute read
- Media CoverageRichard Hughes Quoted in "HIV Prevention Drug Uptake Threatened in Obamacare Battle"2 minute read
- Firm Announcements
Jessika Tuazon Named to the 2023 Southern California Rising Stars List
6 minute read - PublicationsBy Leaving "Therapeutic Alternatives" Undefined, CMS Tilts the Playing Field of Drug Price Negotiations3 minute read
- PublicationsFDA Issues Draft Recommendations for Implementing Decentralized Clinical Trials20 minute read
- PublicationsCMS Seeks Comment on Initial Guidance for the Part D Manufacturer Discount Program: Inflation Reduction Act Updates ...2 minute read
- PublicationsFTC Makes Case for Increased Enforcement2 minute read
- PublicationsFalse Claims Act: Businesses Should Consider How to Document Their Interpretations3 minute read
- PublicationsSupreme Court Determines That Constitutionality of FTC’s Administrative Review Process Can Be Challenged in Federal ...2 minute read
- PublicationsCMS Issues an Information Collection Request for the Drug Price Negotiation Process: Inflation Reduction Act Updates ...3 minute read
- Media CoverageRichard Hughes Quoted in “Could Government Drug-Price Negotiations Sound the Death Knell for Biotech Stocks?” ...3 minute read
- BlogsThe Legal Battle Over Mifepristone10 minute read
- Media CoverageDelia Deschaine Quoted in “Abortion Pill Legal Fight Leaves FDA Grappling with Response”4 minute read
- Media CoverageGeorge Breen Quoted in “Landmark FCA Showdown Looking Like Defense Bar Letdown"2 minute read
- Media CoverageGeorge Breen Quoted in “Justices Appear Open to Whistleblowers’ Drug Fraud Arguments”2 minute read
- Media CoverageDelia Deschaine Quoted in “Employers Pause Plans to Make Abortion Pills Easier to Access”3 minute read
- PublicationsIs CMS Ignoring the Realities of Biopharmaceutical Costs?2 minute read
- Media CoverageDelia Deschaine Quoted in “Blue States Stockpile Abortion Pills Amid Legal Uncertainty”4 minute read
- PublicationsCMS’s Initial Guidance on Medicare Drug Price Negotiation Program Suggests Familiar Pharmacy Chargeback Process ...12 minute read
- PublicationsNew HSR Filing Fee Tier System in Effect2 minute read
- Media CoverageDelia Deschaine Quoted in “Doctors Seek Clarity from FDA as States Stockpile Abortion Pills”2 minute read
- PublicationsCMS Issues an Information Collection Request on Negotiation Data Elements: Inflation Reduction Act Updates3 minute read
- BlogsIs CMS Ignoring the Realities of Biopharmaceutical Costs?6 minute read
- PublicationsReminder of March 31 “Right to Try” Reporting Deadline8 minute read
- Firm Announcements
Epstein Becker Green Recognized Among Top 10 Largest Health Care Law Firms by Modern Healthcare
2 minute read